Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$133.36

(0.00%)

12:52
04/19/18
04/19
12:52
04/19/18
12:52

GW Pharmaceuticals announces FDA advisors' backing for approval of cannabidiol

GW Pharmaceuticals, along with its U.S. subsidiary Greenwich Biosciences, announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration unanimously recommended supporting the approval of the New Drug Application for the investigational cannabidiol oral solution, also known as Epidiolex, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older. If approved, Epidiolex would be the first pharmaceutical formulation of purified, plant-based CBD, a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs. LGS and Dravet syndrome, which develop in childhood, are devastating forms of epilepsy with high morbidity and mortality rates and a significant burden on families and caregivers. More than 90% of patients with LGS or Dravet syndrome have multiple seizures per day, which puts them at constant risk for falls and injury. Physicians who treat LGS and Dravet syndrome patients struggle to reduce the sheer volume of dangerous seizures with currently available therapies. If approved, Epidiolex would be the first-ever FDA-approved medicine for Dravet syndrome patients. "We are pleased by the Advisory Committee's unanimous recommendation to approve Epidiolex, which would provide an important treatment option for patients with LGS and Dravet syndrome, two of the most severe and treatment-resistant forms of epilepsy," said GW's CEO Justin Gover. "This favorable outcome marks an important milestone in our company's unwavering commitment to address the significant unmet need for patients with LGS and Dravet syndrome and our resolve to study Epidiolex under the highest research and manufacturing standards. We look forward to our ongoing discussions with the FDA as it continues to review the Epidiolex NDA."

  • 19

    Apr

  • 21

    May

  • 27

    Jun

GWPH GW Pharmaceuticals
$133.36

(0.00%)

01/23/18
LEER
01/23/18
NO CHANGE
Target $153
LEER
Outperform
Leerink cautiously optimistic ahead of GW Pharmaceuticals CBDV Phase 2 data
Leerink analyst Paul Matteis reiterates an Outperform rating on GW Pharmaceuticals, while lowering his price target on the shares to $153 from $154, ahead of CBDV Phase II data in partial-onset seizures in Q1. While he acknowledges that is difficult to garner conviction in the Phase 2, his analysis of pre-clinical results - compared side-by-side to cannabidiol - instills him with "cautious optimism" on the program, while he believes that the little credit priced into the stock for CBDV sets up an upside skewed risk/reward on the upcoming data readout this quarter.
02/06/18
CANT
02/06/18
NO CHANGE
Target $192
CANT
Overweight
GW Pharmaceuticals price target lowered to $192 from $208 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros lowered his price target for GW Pharmaceuticals to $192 following the company's Q1 financial results and recent equity raise. The analyst, however, believes the shares remain "significantly undervalued," based on his assessment of Epidiolex's opportunity in treating orphan pediatric epileptic conditions. He reiterates an Overweight rating on GW.
02/22/18
CANT
02/22/18
NO CHANGE
Target $192
CANT
Overweight
GW Pharmaceuticals shares could recover quickly, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros believes GW Pharmaceuticals shares could recover quickly from the selloff on the negative results with GWP42006 in adult patients with focal seizures. The analyst highlights the announcement of an advisory committee hearing for Epidiolex on April 18. The "clear near-term focus" is the successful commercialization of Epidiolex for pediatric pharmacoresistant seizures upon potential approval in the second half of 2018, Piros tells investors in a research note. He keeps an Overweight rating on GW shares with a $192 price target.
04/19/18
CANT
04/19/18
NO CHANGE
Target $205
CANT
Overweight
GW Pharmaceuticals price target raised to $205 from $192 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for GW Pharmaceuticals to $205 and reiterates an Overweight rating on the shares after an FDA advisory committee voted 13-0 that the benefit-risk profile of cannabidiol is favorable for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older.

TODAY'S FREE FLY STORIES

VFC

VF Corp.

$82.17

0.89 (1.10%)

15:30
05/24/18
05/24
15:30
05/24/18
15:30
Options
Defensive short-term play opened in VF Corp »

Defensive short-term play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$82.78

1.71 (2.11%)

15:29
05/24/18
05/24
15:29
05/24/18
15:29
Hot Stocks
PayPal sees FXN revenue growth of 17%-18% CAGR over medium-term »

Sees non-GAAP EPS growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

  • 12

    Jun

PYPL

PayPal

$82.56

1.49 (1.84%)

15:26
05/24/18
05/24
15:26
05/24/18
15:26
Hot Stocks
PayPal targeting $1B-$3B per year for M&A »

PayPal CFO John Rainey is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

  • 12

    Jun

JNJ

Johnson & Johnson

$122.16

-1.3 (-1.05%)

15:26
05/24/18
05/24
15:26
05/24/18
15:26
Hot Stocks
Jury delivers $25.75M verdict in Johnson & Johnson baby powder case »

A jury in California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

15:25
05/24/18
05/24
15:25
05/24/18
15:25
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

LXFT

Luxoft

$32.80

-10.55 (-24.34%)

15:23
05/24/18
05/24
15:23
05/24/18
15:23
Downgrade
Luxoft rating change  »

Luxoft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

PYPL

PayPal

$82.25

1.18 (1.46%)

15:19
05/24/18
05/24
15:19
05/24/18
15:19
Hot Stocks
PayPal at session highs, up 2% to $82.63 as CFO presents at investor day »

PayPal CFO John Rainey is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

  • 12

    Jun

GPS

Gap

$32.87

0.9 (2.82%)

15:19
05/24/18
05/24
15:19
05/24/18
15:19
Options
Gap options imply 9.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

TMUS

T-Mobile

$57.03

0.01 (0.02%)

15:17
05/24/18
05/24
15:17
05/24/18
15:17
Periodicals
T-Mobile glitch let anyone access customer account data, ZDNet reports »

A glitch in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
05/24/18
05/24
15:17
05/24/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
05/24/18
05/24
15:16
05/24/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,605.50

3.73 (0.23%)

15:14
05/24/18
05/24
15:14
05/24/18
15:14
Periodicals
Family claims Amazon device recorded, shared private conversation, Kiro7 says »

A Portland family has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

ADSK

Autodesk

$139.19

-0.11 (-0.08%)

15:04
05/24/18
05/24
15:04
05/24/18
15:04
Options
Autodesk options imply 8.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 14

    Jun

SJM

J.M. Smucker

$109.22

-0.98 (-0.89%)

15:00
05/24/18
05/24
15:00
05/24/18
15:00
Options
Notable spread in JM Smucker »

Notable spread in JM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

  • 15

    Aug

DB

Deutsche Bank

$12.29

-0.605 (-4.69%)

14:58
05/24/18
05/24
14:58
05/24/18
14:58
Periodicals
Deutsche Bank shareholders vote down motion to remove Chairman, Reuters says »

About 91% of Deutsche…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$61.03

-0.36 (-0.59%)

14:51
05/24/18
05/24
14:51
05/24/18
14:51
Hot Stocks
Total acquires 10% interest in Novatek's Arctic LNG 2 project »

Chairman of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IGLD

Internet Gold

$3.38

0.37 (12.29%)

14:49
05/24/18
05/24
14:49
05/24/18
14:49
Technical Analysis
Technical Take: Internet Gold spikes after results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$56.05

-0.19 (-0.34%)

14:49
05/24/18
05/24
14:49
05/24/18
14:49
Options
Nutanix options imply 13.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 07

    Jun

  • 10

    Jul

TAHO

Tahoe Resources

$5.11

-0.195 (-3.68%)

14:45
05/24/18
05/24
14:45
05/24/18
14:45
Options
Tahoe Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$72.03

0.71 (1.00%)

, UA

Under Armour

$18.34

0.45 (2.52%)

14:29
05/24/18
05/24
14:29
05/24/18
14:29
Periodicals
Nike to take MLB on-field rights from Under Armour in 2020 season, SBD says »

MLB's on-field…

NKE

Nike

$72.03

0.71 (1.00%)

UA

Under Armour

$18.34

0.45 (2.52%)

UAA

Under Armour

$20.50

0.43 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

IGLD

Internet Gold

$3.22

0.21 (6.98%)

14:25
05/24/18
05/24
14:25
05/24/18
14:25
Earnings
Internet Gold jumps 20% to $3.65 after disclosing Q1 results 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IP

International Paper

$54.61

-0.145 (-0.26%)

14:20
05/24/18
05/24
14:20
05/24/18
14:20
Options
2X average daily option volume in International Paper and calls lead puts 11:1 »

2X average daily option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
05/24/18
05/24
14:17
05/24/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
05/24/18
05/24
14:16
05/24/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YNDX

Yandex

$33.72

-0.83 (-2.40%)

14:15
05/24/18
05/24
14:15
05/24/18
14:15
Options
Yandex put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.